Safety Profile
Known Safety Concerns
- FDA banned bulk pure caffeine powder for consumer sale
- Fatal overdose documented from pure powdered caffeine
- High doses: anxiety, tachycardia, hypertension, seizures
- OFDA limits OTC serving to 200 mg -- check pre-workout combined doses
Contraindications
- FDA banned bulk pure caffeine powder for consumer sale
- Fatal overdose documented from pure powdered caffeine
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Synthetic caffeine is chemically identical to naturally derived caffeine but is produced via chemical synthesis rather than plant extraction. It is absorbed faster than caffeine from beverages and is the primary form in pre-workout supplements, energy pills, and caffeine tablets. The FDA limits OTC caffeine to 200 mg per serving. Doses above 400 mg/day are associated with anxiety, tachycardia, and sleep disruption. Fatal doses have been reported from pure powdered caffeine — the FDA has banned bulk pure caffeine sales to consumers.
Biological and Chemical Classification
- Scientific Name
- Synthetic caffeine (1,3,7-trimethylxanthine)
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 6 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Stimulant
- Evidence consistency: High consistency across studies (100%)
- FDA banned bulk pure caffeine powder for consumer sale
- Fatal overdose documented from pure powdered caffeine
- High doses: anxiety, tachycardia, hypertension, seizures
- OFDA limits OTC serving to 200 mg -- check pre-workout combined doses
The available scientific evidence for Synthetic Caffeine indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 6/40 |
| Evidence consistency | 20/20 |
| Safety signals | 8/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 6 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 6 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 25 მარ 2026, 12:45
Evidence Distribution
-
Observational / other LOW evidence YELLOWSynergistic Actions of Natural Compounds for Enhancing Cognitive and Physical Performance: A Narrative Review. ↗Panda R et al.. Synergistic Actions of Natural Compounds for Enhancing Cognitive and Physical Performance: A Narrative Review.. Cureus. 2026. PMID:41777984.PMID 41777984 ↗Journal CureusYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41777984/
-
Observational / other LOW evidence YELLOWNew Synthetic Caffeine Analogs as Modulators of the Cholinergic System. ↗Fabiani C et al.. New Synthetic Caffeine Analogs as Modulators of the Cholinergic System.. Mol Pharmacol. 2022. PMID:34969831.PMID 34969831 ↗Journal Mol PharmacolYear 2022Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/34969831/
-
Observational / other LOW evidence YELLOWDetection and determination of undeclared synthetic caffeine in weight loss formulations using HPLC-DAD and UHPLC-MS/MS. ↗Viana C et al.. Detection and determination of undeclared synthetic caffeine in weight loss formulations using HPLC-DAD and UHPLC-MS/MS.. J Pharm Anal. 2018. PMID:30595942.PMID 30595942 ↗Journal J Pharm AnalYear 2018Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/30595942/
-
Observational / other LOW evidence YELLOW8-(3-phenylpropyl)-1,3,7-triethylxanthine is a synthetic caffeine substitute with stronger metabolic modulator activity. ↗Carrageta DF et al.. 8-(3-phenylpropyl)-1,3,7-triethylxanthine is a synthetic caffeine substitute with stronger metabolic modulator activity.. Toxicol In Vitro. 2018. PMID:30098389.PMID 30098389 ↗Journal Toxicol In VitroYear 2018Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/30098389/
-
Observational / other LOW evidence YELLOWA Prospective Randomized, Double-Blind, Two-Period Crossover Pharmacokinetic Trial Comparing Green Coffee Bean Extract-A Botanically Sourced Caffeine-With a Synthetic USP Control. ↗Morton K et al.. A Prospective Randomized, Double-Blind, Two-Period Crossover Pharmacokinetic Trial Comparing Green Coffee Bean Extract-A Botanically Sourced Caffeine-With a Synthetic USP Control.. Clin Pharmacol Drug Dev. 2018. PMID:29659178.PMID 29659178 ↗Journal Clin Pharmacol Drug DevYear 2018Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/29659178/
-
Observational / other LOW evidence YELLOWThe Safety of Ingested Caffeine: A Comprehensive Review. ↗Temple JL et al.. The Safety of Ingested Caffeine: A Comprehensive Review.. Front Psychiatry. 2017. PMID:28603504.PMID 28603504 ↗Journal Front PsychiatryYear 2017Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/28603504/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Synthetic Caffeine. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a moderate safety concern. Caution is advised, particularly at high doses or in sensitive populations.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Moderate classification for Synthetic Caffeine
A score of 5.5 places this ingredient in the Moderate band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.